Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05333107 · ClinicalTrials.gov registry record · Phase 1
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II
A Phase 1 study of Healthy Volunteers; High Cholesterol, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 2
- Study locations
NCT05333107 is a Phase 1 study of Healthy Volunteers; High Cholesterol that has completed, run by Novo Nordisk A/S. The registered enrollment target is 152 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT05333107, a Phase 1 study of Healthy Volunteers; High Cholesterol, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol). Participants will only receive 2 of the 3 tablet formulations. The treatments participants get are decided by chance. Participants will receive 1 formulation for 10 days (first treatment period) and the other formulation for 5 days (second treatment period). The study will last up to 96 days. Only men can participate in this clinical study.
Conditions Studied
Interventions
- DRUG NNC0385-0434 G
- DRUG NNC0385-0434 F
- DRUG NNC0385-0434 B
Study Locations (2)
California
- Altasciences - Cypress
- Altasciences Clinical Los Angeles, Inc. - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2022-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05333107
The ClinicalTrials.gov registry entry for NCT05333107 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers; High Cholesterol appearing as the primary indexed condition, and to 3 interventions - of which NNC0385-0434 G is the first listed.
NCT05333107 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05333107 about?
NCT05333107 is a clinical study titled "A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II". In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol). Participants will only receive 2 of the 3 tablet formulations. The treatments participants get are decided...
What is the current status of trial NCT05333107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2022-04-12. Estimated completion is 2022-09-23.
What conditions does trial NCT05333107 study?
This clinical trial studies the following conditions: Healthy Volunteers; High Cholesterol.
What interventions are being tested in trial NCT05333107?
The interventions under investigation include: NNC0385-0434 G (DRUG), NNC0385-0434 F (DRUG), NNC0385-0434 B (DRUG).
Who is sponsoring clinical trial NCT05333107?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05333107 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.